Trials / Completed
CompletedNCT00478634
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
An Open-label, Multicenter Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab (if Given as Part of Local Standard Practice) in Patient With Metastatic Colorectal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAD001, Cetuximab, Irinotecan |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2007-05-25
- Last updated
- 2012-11-02
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00478634. Inclusion in this directory is not an endorsement.